Oncolytic potency of HER-2 retargeted VSV-FH hybrid viruses: The role of receptor ligand affinity

Camilo Ayala Breton, Nitwara Wikan, Arinda Abbuhl, Duncan R. Smith, Stephen J Russell, Kah-Whye Peng

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

The hybrid oncolytic vesicular stomatitis virus (VSV-FH) deleted for its G glycoprotein and displaying the measles virus (MV) envelope glycoproteins (hemagglutinin H and fusion F) is fusogenic, infects cells via any of the three MV receptors and has potent oncolytic activity against subcutaneous and disseminated myeloma tumors. To tailor VSV-FH as an oncolytic virus for ovarian cancer, we ablated its natural tropism and retargeted the virus by display of a single-chain antibody (scFv) with specificity to the HER-2/neu receptor. A panel of six VSVFH-αHER2 viruses displaying anti-HER2 scFv that bind to the same HER2 epitope but with different Kd (10-6 to 10-11 M, VSVFH-áHER2#6 to #11, respectively) were rescued and characterized. A Kd of at least 10.8 M is required for infection of HER-2 positive SKOV3ip.1 cells. The higher affinity viruses (10-8M) were able to infect and fuse SKOV3ip.1 cells more efficiently, inducing more extensive cytopathic effects. We next compared the antitumor potency of the viruses against SKOV3ip.1 tumor xenografts. In contrast to the saline-treated animals, one intratumoral injection of VSVFH-áHER2#9, #10, or #11 resulted in efficient tumor control. There was no significant difference between viruses with an affinity higher than 10.9 M in terms of oncolytic potency. VSVFH-áHER2 virus may be a promising agent for the treatment of HER-2 positive malignancies.

Original languageEnglish (US)
Article number15012
JournalMolecular Therapy - Oncolytics
Volume2
DOIs
StatePublished - Aug 5 2015

    Fingerprint

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Oncology
  • Pharmacology (medical)

Cite this